CA
NZ
UK
AU
IND
US
…
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Thermo Fisher Scientific provides instruments, reagents, consumables, software and contract services to pharmaceutical, biotech, clinical and academic laboratories worldwide. Growth may be supported by expanding R&D and biologics manufacturing, rising diagnostics and genomics demand, lab automation and recurring consumable sales, while scale and product breadth could make its revenue mix attractive to investors.
Key risks include acquisition integration and execution risk, sensitivity to R&D and capital spending cycles, and regulatory, supply‑chain or geopolitical disruptions that investors should monitor.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 7835.00M | 8841.00M | 7225.00M | 4070.00M | 3262.00M |
| Minority interest | -10.00M | -3.00M | - | - | - |
| Net income | 6950.00M | 7725.00M | 6375.00M | 3696.00M | 2938.00M |
| Selling general administrative | 7127.00M | 6842.00M | 6930.00M | 6144.00M | 6057.00M |
| Gross profit | 19500.00M | 20234.00M | 16505.00M | 11827.00M | 11364.00M |
| Reconciled depreciation | 3381.00M | 2592.00M | 2325.00M | 2277.00M | 2267.00M |
| Ebit | 8393.00M | 10028.00M | 7794.00M | 4594.00M | 3979.00M |
| Ebitda | 12056.00M | 12166.00M | 10202.00M | 6610.00M | 6246.00M |
| Depreciation and amortization | 3663.00M | 2138.00M | 2408.00M | 2016.00M | 2267.00M |
| Non operating income net other | -4.00M | -655.00M | -16.00M | 152.00M | - |
| Operating income | 8393.00M | 10028.00M | 7794.00M | 4594.00M | 3783.00M |
| Other operating expenses | 36408.00M | 28986.00M | 24325.00M | 21361.00M | 20525.00M |
| Interest expense | 726.00M | 536.00M | 553.00M | 676.00M | 667.00M |
| Tax provision | 703.00M | 1109.00M | 850.00M | 374.00M | 324.00M |
| Interest income | 272.00M | 43.00M | 488.00M | 224.00M | 137.00M |
| Net interest income | -454.00M | -493.00M | -488.00M | -452.00M | -530.00M |
| Extraordinary items | - | - | 0.00M | -8.00M | -117.00M |
| Non recurring | 114.00M | 197.00M | 99.00M | -413.00M | 50.00M |
| Income tax expense | 703.00M | 1109.00M | 850.00M | 374.00M | 324.00M |
| Total revenue | 44915.00M | 39211.00M | 32218.00M | 25542.00M | 24358.00M |
| Total operating expenses | 10993.00M | 10009.00M | 8612.00M | 7646.00M | 7531.00M |
| Cost of revenue | 25415.00M | 18977.00M | 15713.00M | 13715.00M | 12994.00M |
| Total other income expense net | -558.00M | -1187.00M | -569.00M | -524.00M | -41.00M |
| Net income from continuing ops | 6960.00M | 7728.00M | 6375.00M | 3696.00M | 2938.00M |
| Net income applicable to common shares | 6950.00M | 7725.00M | 6375.00M | 3696.00M | 2938.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 97154.00M | 95123.00M | 69052.00M | 58381.00M | 56232.00M |
| Intangible assets | 17478.00M | 20146.00M | 12685.00M | 14014.00M | 14978.00M |
| Other current assets | 1644.00M | 1640.00M | 1131.00M | 1172.00M | 922.00M |
| Total liab | 53006.00M | 54146.00M | 34535.00M | 28706.00M | 28646.00M |
| Total stockholder equity | 43978.00M | 40793.00M | 34507.00M | 29675.00M | 27586.00M |
| Deferred long term liab | 2849.00M | 3837.00M | 1794.00M | 2192.00M | 2265.00M |
| Other current liab | 5449.00M | 5377.00M | 4230.00M | 2685.00M | 4532.00M |
| Common stock | 441.00M | 439.00M | 437.00M | 434.00M | 432.00M |
| Capital stock | 441.00M | 439.00M | 437.00M | 434.00M | 432.00M |
| Retained earnings | 41910.00M | 35431.00M | 28116.00M | 22092.00M | 18696.00M |
| Other liab | 5689.00M | 8138.00M | 5134.00M | 4849.00M | 4651.00M |
| Good will | 41196.00M | 41924.00M | 26041.00M | 25714.00M | 25347.00M |
| Other assets | 2224.00M | 3013.00M | 1629.00M | 1245.00M | 1053.00M |
| Cash | 8524.00M | 4477.00M | 10325.00M | 2399.00M | 2103.00M |
| Cash and equivalents | 8524.00M | 4477.00M | 10325.00M | 2399.00M | 2103.00M |
| Total current liabilities | 17010.00M | 13436.00M | 10304.00M | 6197.00M | 6147.00M |
| Current deferred revenue | 2601.00M | 2655.00M | 1271.00M | 916.00M | 809.00M |
| Net debt | 25964.00M | 30393.00M | 11410.00M | 15353.00M | 16887.00M |
| Short term debt | 5579.00M | 2537.00M | 2628.00M | 676.00M | 1271.00M |
| Short long term debt | 5579.00M | 2537.00M | 2628.00M | 676.00M | 1271.00M |
| Short long term debt total | 34488.00M | 34870.00M | 21735.00M | 17752.00M | 18990.00M |
| Other stockholder equity | 1627.00M | 4923.00M | 5954.00M | 7149.00M | 8458.00M |
| Property plant equipment | 9280.00M | 8333.00M | 5912.00M | 4749.00M | 4165.00M |
| Total current assets | 25229.00M | 20113.00M | 21957.00M | 11893.00M | 10625.00M |
| Long term investments | - | - | - | 67.00M | 64.00M |
| Net tangible assets | -14544.00M | -21182.00M | -4219.00M | -10053.00M | -12739.00M |
| Short term investments | 2.00M | - | 28.00M | 37.00M | 31.00M |
| Net receivables | 9427.00M | 8945.00M | 6472.00M | 4952.00M | 4595.00M |
| Long term debt | 28909.00M | 32333.00M | 19107.00M | 17076.00M | 17719.00M |
| Inventory | 5634.00M | 5051.00M | 4029.00M | 3370.00M | 3005.00M |
| Accounts payable | 3381.00M | 2867.00M | 2175.00M | 1920.00M | 1615.00M |
| Noncontrolling interest in consolidated entity | 54.00M | 62.00M | - | - | - |
| Accumulated other comprehensive income | -3099.00M | -2329.00M | -2807.00M | -2679.00M | -2498.00M |
| Common stock total equity | 441.00M | 439.00M | 437.00M | 434.00M | 432.00M |
| Retained earnings total equity | 41910.00M | 35431.00M | 28116.00M | 22092.00M | 18696.00M |
| Treasury stock | - | -8922.00M | -6818.00M | -5236.00M | -3665.00M |
| Non currrent assets other | -2849.00M | 4352.00M | 2457.00M | 1850.00M | 1051.00M |
| Non current assets total | 69701.00M | 71997.00M | 45466.00M | 45243.00M | 44554.00M |
| Long term debt total | 28909.00M | 32333.00M | 19107.00M | 17076.00M | 17719.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2159.00M | -21932.00M | -1510.00M | -1487.00M | -1253.00M |
| Change to liabilities | 648.00M | 479.00M | 59.00M | 476.00M | 159.00M |
| Total cashflows from investing activities | -2159.00M | -21932.00M | -1510.00M | -1487.00M | -1253.00M |
| Net borrowings | 654.00M | 8911.00M | 2747.00M | -1405.00M | -1556.00M |
| Total cash from financing activities | -2810.00M | 6581.00M | 959.00M | -3118.00M | -2237.00M |
| Change to operating activities | -442.00M | -1558.00M | -395.00M | -248.00M | -81.00M |
| Net income | 6960.00M | 7728.00M | 6375.00M | 3696.00M | 2938.00M |
| Change in cash | 4046.00M | -5845.00M | 7914.00M | 305.00M | 756.00M |
| Begin period cash flow | 4491.00M | 10336.00M | 2422.00M | 2117.00M | 1361.00M |
| End period cash flow | 8537.00M | 4491.00M | 10336.00M | 2422.00M | 2117.00M |
| Total cash from operating activities | 9154.00M | 9543.00M | 8289.00M | 4973.00M | 4543.00M |
| Issuance of capital stock | - | - | - | 153.00M | 0.00M |
| Depreciation | 3381.00M | 2592.00M | 2325.00M | 2277.00M | 2267.00M |
| Other cashflows from investing activities | 84.00M | -34.00M | -36.00M | -561.00M | -495.00M |
| Dividends paid | -455.00M | -395.00M | -337.00M | -297.00M | 266.00M |
| Change to inventory | -825.00M | -1065.00M | -508.00M | -458.00M | -324.00M |
| Change to account receivables | -430.00M | -204.00M | -1302.00M | -225.00M | -366.00M |
| Sale purchase of stock | -3000.00M | -2000.00M | -1500.00M | -1500.00M | -500.00M |
| Other cashflows from financing activities | 4710.00M | -91.00M | -147.00M | 8350.00M | 5699.00M |
| Change to netincome | -179.00M | 781.00M | -112.00M | -385.00M | -185.00M |
| Capital expenditures | 2243.00M | 2523.00M | 1474.00M | 926.00M | 758.00M |
| Change receivables | -430.00M | -204.00M | -1302.00M | -225.00M | -366.00M |
| Cash flows other operating | -401.00M | -724.00M | 7827.00M | 3288.00M | 2992.00M |
| Cash and cash equivalents changes | 4185.00M | -6039.00M | 7738.00M | 368.00M | 1053.00M |
| Change in working capital | -1049.00M | -1558.00M | -395.00M | -619.00M | -530.00M |
| Stock based compensation | 307.00M | 230.00M | 196.00M | 181.00M | 181.00M |
| Other non cash items | 550.00M | 957.00M | 340.00M | -214.00M | 106.00M |
| Free cash flow | 6911.00M | 7020.00M | 6815.00M | 4047.00M | 3785.00M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc |
8.13 1.19% |
693.02 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.97 0.42% |
232.00 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.56 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-1.27 5.08% |
23.74 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
| NTRA Natera Inc |
5.92 1.46% |
410.82 | - | 5000.00 | 18.68 | 27.76 | 18.36 | -26.80 |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
168 Third Avenue, Waltham, MA, United States, 02451
781 622 1000
130000
| Name | Title | Year Born |
|---|---|---|
| Mr. Marc N. Casper | Chairman, Pres & CEO | 1968 |
| Mr. Stephen Williamson | Sr. VP & CFO | 1967 |
| Mr. Michel Lagarde | Exec. VP & COO | 1975 |
| Mr. Gianluca Pettiti | Exec. VP | 1979 |
| Mr. Joseph R. Holmes | VP & Chief Accounting Officer | 1980 |
| Mr. Ryan J. Snyder | Sr. VP & Chief Information Officer | NA |
| Dr. Karen E. Nelson Ph.D. | Chief Scientific Officer & Member of Scientific Advisory Board | NA |
| Mr. Rafael Tejada | VP of Investor Relations | NA |
| Mr. Michael A. Boxer Esq. | Sr. VP, Gen. Counsel & Sec. | 1962 |
| Ms. Sandy B. Pound | VP & Chief Communications Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...